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ABSTRACT receptor. The signal is detected after a short third incubation step 
Confirmation of the diagnosis of GH deficiency in adults and chil- with labeled streptavidin. The assay is sensitive (detection range, 
dren involves provocative testing for human (h) GH. Different com- 0.1-100 Fg/L) and has average inter- and intraassay precisions of 
mercially available immunoassays yield largely discrepant results in 10.3% and 7.3%, respectively. Endogenous GH-binding protein does 
the measurement of GH levels in human serum. These discrepancies not interfere with the hGH result; placental lactogen shows no de- 
result in doubtful relevance of cut-off levels proposed for GH provoc- tectable cross-reaction in this immunofunctional assay. The degree of 
ative testing. We have developed an immunofunctional assay method immunofunctionally active hGH forms in serum samples, calculated 
that allows quantitation of only those GH forms in circulation that by comparison of immunofunctional assay and RIA results, varied 
possess both binding sites of the hormone for its receptor and thus can between 52-93%‘. We propose this immunofunctional assay for GH 
initiate a biological signal in target cells. An anti-hGH monoclonal measurement as a new reference method for hGH quantitation in 
antibody recognizing binding site 2 of hGH is immobilized and used serum. The immunofunctional assay translates only hGH forms into 
to capture hGH from the serum sample. Biotin-labeled recombinant an assay signal that are capable of dimerizing GH receptors and, thus, 
GH-binding protein in a second incubation step forms a complex with ofinitiating a biological effect in target cells. (JClin Endocrinol Metab 
those hGH molecular isoforms that have both binding sites for the 81: 2613-2620, 1996) 
T HE DETERMINATION of circulating levels of human (h)GH in serum is generally accomplished by the use 
of commercially available immunoassay kits. The compara- 
tive measurement of serum samples by different immuno- 
assay kits results in vastly discrepant results, although most 
commercial immunoassay kits for GH determination are cal- 
ibrated against international reference preparations of the 
hormone (l-3). This heterogeneity of hGH concentrations 
measured by different immunoassay kits has been attributed 
to the use of different reference preparations (4), to the het- 
erogeneity of different forms of GH in circulation (5,6), the 
epitope specificity of the antibodies employed (7), and dif- 
ferences in standard matrix (8). 
The diagnostic procedures in the evaluation of suspected 
GH deficiency in childhood (9,lO) and recently also in adult 
patients (11) involve GH measurement after provocative 
tests. The results obtained by these measurements have pro- 
found effects on establishment of the diagnosis and represent 
the key criteria for reimbursement of the GH replacement 
therapy costs. Although recommendations exist concerning 
the provocative testing procedures for the diagnosis of GH 
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deficiency, and cut-off levels have been proposed below 
which the peak GH levels after provocative tests should be, 
no consensus has been achieved or proposed for the bio- 
chemical procedure of GH measurement itself. 
The essential information requested by blood sampling for 
GH determination is the amount of biologically active, func- 
tional GH in the circulation at the time of blood sampling. 
The answer commonly provided by the analytical results, in 
contrast, represents a quantitation of immunoreactive GH 
molecular forms in the sample, to which variants, fragments, 
and aggregates of GH (6) contribute to different extents de- 
pending on the epitope specificity of the antibodies em- 
ployed in the assay (1, 12). 
hGH has been shown to induce dimerization of its receptor 
as the initial step of signal transduction in target cells (13), 
which leads to phosphorylation of the intracellular domain 
of the hGH receptor and receptor-associated proteins (14). 
This process initiates the signal transduction cascade involv- 
ing JAK2 kinase and STAT (Signal Transducence and Acti- 
vation of Transcription) proteins (15, 16). The x-ray crystal- 
lography structure of a complex formed by one molecule of 
GH and two GH receptor ecto domains was resolved (171, 
and the epitopes of the hGH molecule interacting with either 
receptor molecule have been characterized. The GH mole- 
cule sequentially binds to a first receptor molecule with a 
large contact surface area involving a total of 31 amino acid 
side-chains (18) of the C-terminal part of the fourth helix 
bundle, parts of the random coil sequence between helix 1 
and helix 2, and parts of helix 1 (13, 19). Consecutively, this 
1:l complex associates a second receptor molecule via bind- 
ing site 2 of hGH, which represents a much smaller surface 
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area on the N-terminal random coil sequence, the beginning 
of helix 1 and C-terminal parts of helix 3 of the hGH molecule 
(13). 
We have sought to identify monoclonal antibodies (mAbs) 
specific for both binding domains on the hGH molecule that 
interact with the receptor molecules and attempted to design 
an immunoassay procedure more closely reflecting in its 
results the biologically active proportion of GH in a given 
serum sample (7). As the epitope recognized by mAbs gen- 
erally spans over 3-10 amino acid residues (201, no single 
mAb could be identified representatively binding to the 31 
amino acid side-chains involved in interaction on binding 
site 1 with the receptor (18). 
This article describes our approach to design an immuno- 
functional assay (IFA) for hGH in which only those molec- 
ular forms of hGH in the sample to be analyzed translate into 
an assay signal that is also capable of inducing a receptor 
dimerization and thereby initiating the signal transduction 
process on target cells. The IFA is based on the interaction of 
GH with an immobilized mAb specific for binding site 2 of 
the hormone and with biotin-labeled recombinant hGH 
(rhGH)-binding protein (hGHBP), which represents the full- 
length GH receptor ecto domain. 
Materials and Methods 
Reagents 
Twenty-two-kilodalton rhGH, 20-kDa rhGH, and rhGH dimers were 
provided by Eli Lilly Co. (Indianapolis, IN). The recombinant reference 
preparation 88/624 of hGH was obtained from NIBSC (Hartfordshire, 
UK). Defined fragments of hGH derived from enzymatic or chemical 
cleavage were kindly donated by Dr. Jack Kostyo (Ann Arbor, MI). 
Recombinant mutants of hGH lacking the first 7 or 13 amino acid 
residues, respectively, were gifts from Dr. Tikva Vogel, Biotechnology 
General (Nesziona, Israel). A recombinant variant of hGH in which the 
C-terminal 9 of 13 amino acids that are heterologous between pituitary 
hGH and placental GH are mutated to the placental variant with the 
remainder of the sequence according to the pituitary GH was a gift from 
Dr. Par Gellerfors, Kabi Pharmacia (Stockholm, Sweden). Pituitary-de- 
rived 22-kDa hGH (AFP-4793B), 20-kDa hGH (AFP-4286B), and poly- 
clonal anti-GH serum from rabbit (AFP-Cl1981A) were gifts from Dr. A. 
F. Parlow, NIDDK, Harbor-University of Calfiornia-Los Angeles Med- 
ical Center (Torrance, CA). Full-length rhGH receptor ecto domain (ami- 
no acids l-246) was expressed in Escherichiu coli by Dr. G. Crivi, Searle- 
Monsanto (St. Louis, MO) and extracted and refolded from inclusion 
bodies by Dr. A. Gertler (Rehovot, Israel). Human placental lactogen 
(hPL) was purchased from Sigma (Deisenhofen, Germany), and sheep 
serum was obtained from Paa Biologics (Marburg, Germany). All other 
reagents were of analytical grade. 
mAbs to hGH were produced by the myeloma technique (21) and 
propagated in protein-free medium (PFHM II, Life Technologies, Egg- 
enstein, Germany). Anti-hGH mAb 7811 is IgG subtype 1 and has an 
affinity of 3 X lo9 L/mol for 22-kDa hGH. 
Biotinylation of rhGH and rhGHBP 
Biotin-E-amidocaproyl-y-butyryl-N-hydroxysuccinimide ester was 
added in a ZO-fold molecular excess to either rhGH or rhGHBP following 
the protocols described previously (22). The reaction mixtures were left 
for 2 h at ambient temperature and then applied to a Superdex 30 fast 
protein liquid chromatography column for separation of labeled protein 
and uncoupled biotin. The biotinylated proteins were stored in 0.2 
mmol/L Tris-HCl buffer, pH 7.4, containing 1% BSA in aliquots at 
-20 c. 
End-point detection 
Using biotin as a primary probe throughout, the microtiter plates with 
an immobilized reaction partner and a biotinylated assay component 
were washed three times with 0.3 mL wash buffer (50 mmol/L 
Na,HPO,, 2% Tween-40, and 0.1% NaN,, pH 7.5) and then incubated for 
30 min with 10 rig/well europium-labeled streptavidin (Wallac, Turku, 
Finland) in assay buffer [50 mmol/L Tris-(hydroxymethyl)-aminometh- 
ane, 9 g/L NaCl, 0.5 g/L NaN,, 0.1 g/L Tween-40,5 g/L BSA, 0.5 g/L 
bovine y-globulin, and 20 Fmol/L diethylenetriaminepenta acetic acid, 
pH 7.751. After a h-fold wash step, the microtiter plates were filled with 
0.2 mL enhancement solution (Wallac) to transchelate europium into a 
highly fluorescent complex. After 5-15 min of agitation on a horizontal 
shaker, the plate was placed into a Delfia 1232 time-resolved fluorometer 
to read the signal. 
Identification of epitopes recognized by anti-hGH mAbs 
More than 40 mAbs have been produced in our laboratory by im- 
munization of BALB/c mice with recombinant 22-kDa GH in addition 
to anti-hGH-mAbs, previously reported (23). Antibodies were selected 
to have affinities (K,) for hGH of 10” L/mol or more. The epitope 
specificities of the anti-hGH mAbs were characterized by performing 
comparative displacement experiments in which the respective anti- 
bodies were immobilized to polystyrene surfaces, and the 50% intercept 
for displacement of biotin-labeled hGH by 22-kDa GH was compared to 
the 50% intercept of hGH fragments and hGH variants. By analysis of 
the cross-reactivity of a given monoclonal antibody with these hGH- 
related forms and projection of the structural alterations in the hGH 
variants or fragments onto the structural model of the 22.kDa hGH 
molecule derived from x-ray crystallography analysis (17, 24), the re- 
spective epitopes were deduced. 
hGH-ZFA assay standards and patient samples 
hGH calibrators containing pituitary-derived hGH in sheep serum 
were purchased from Medgenix (Fleurus, Belgium). Twenty-two kilo- 
dalton rhGH reference preparation 88/624, containing 2 mg/ampule, 
was dissolved and diluted in sheep serum or a pool of human serum 
previously shown to contain less than 0.1 Kg/L hGH, as measured by 
in-house sandwich immunoassay. 
Patient sera were obtained after written informed consent from pa- 
tients with postoperative hypopituitarism undergoing provocative test- 
ing for hGH secretion and under GH replacement therapy as well as 
from patients with active acromegaly undergoing treatment with so- 
matostatin analogs as well as from sera sent into the pituitary hormone 
laboratory of our university hospital for routine hGH measurement. 
Reference hGH immunoassay 
A competitive polyclonal RIA was performed by use of the polyclonal 
antibody provided by the NIDDK (anti-hGH-2) raised in rabbit, follow- 
ing the procedure suggested by the NIDDK, but using ‘Z”I-labeled re- 
combinant hGH produced by the Iodogen method (25) to a specific 
activity of 82 &i/~g. 
Nb2 cell bioassay for hGH quantification 
The Nb2 assays were carried out in the Section of Pediatric Endo- 
crinology at the Universitits-Kinderklinik (Tubingen, Germany). Nb2 
cl1 cells and anti-hPRL monoclonal antibody 9C3 as ascites fluid were 
kindly provided by Dr. H. Friesen (Winipeg, Canada). The cells were 
expanded in Fischer’s medium with 10% FCS and transferred to Fisch- 
er’s medium with 5% horse serum 48 h before assay [method modified 
after that of Tanaka et nl. (26)]. Two X lo5 cells were plated in 24-well 
microtiter plates and grown in the presence of hGH standard of seven 
concentrations between O-24.5 pg/L or in human serum in the presence 
of a 1:SOOO dilution of the anti-hPRL antibody 9C3 for 72 h. The standards 
were calibrated against International Reference Preparation SO/SOS. The 
cell number was determined by a Coulter counter (Cobas Minos STE, 
Hoffman LaRoche, Grenzach, Germany), and the number of cell dou- 
blings was calculated. For estimation of the hGH concentrations in the 
serum samples, the rate of doublings obtained in the serum under 
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neutralizing conditions of the anti-hPRL antibody was compared to the 
number of doublings achieved by the standard concentrations of hGH. 
IFA procedure 
Anti-hGH mAb 7Bl1, which binds to an epitope largely overlapping 
with binding site 2 of the hGH molecule, was adsorbed to 96.well flat 
bottom microtiter plates (Nunc, Roskilde, Denmark) by incubation of 
500 ng mAb 7811 in 200 FL 50 mmol/L sodium phosphate buffer, pH 
9.6. The plates were sealed with a self-adhesive cover film and stored at 
4 C for 12 h to 1 month. After aspiration of the coating solution, the plates 
were washed three times with washing solution. 
Twenty-five microliters of standard or sample were pipetted into the 
wells, followed by 175 PL assay buffer. The plates were incubated at 
ambient temperature for 3 h on a horizontal shaker. After a 3-fold wash 
step, 50 rig/well biotinylated rhGHBP were added in 200 FL assay 
buffer, and the plates were sealed and incubated overnight (12-16 h) at 
4 C. After a 3-fold wash step, the plates were incubated with strepta- 
vidin-europium and processed as described above. Figure 1 shows the 
complex of antibinding site 2 antibody mAb 7811 immobilized to the 
microtiter plate, hGH, and the biotinylated rhGHBP that binds to bind- 
ing site 1 as well as the streptavidin-europium complex binding to the 
biotin moiety of this conjugate. The calibration curve was produced by 
plotting the hGH concentration of standards and the signal from the 
time-resolved fluorometric end point in a double logarithmic system and 
using a spline-fit as provided in the Multicalc software package (Wallac). 
Concentrations of unknown samples were read by interpolation of the 
signal obtained on the standard curve. 
Study of interference from endogenous GHBP on hGH IFA 
results 
To investigate a potential bias produced by endogenous hGHBP on 
the reading obtained from the hGH IFA, increasing concentrations of 
rhGHBP were incubated overnight at 4 C with rhGH at concentrations 
of 1, 4, 14, and 40 wg/L. rhGHBP concentrations between 500-10,000 
pmol/L were used. The reagent mixtures were allowed to form com- 
plexes and then assayed in the hGH IFA as unknown samples using a 
standard curve of rhGH in assay buffer. 
Displacement of biotinylated rhGHBP from immobilized 
hGH by epitope-specific mAbs 
mAb lOA (IgG,; K, for 22-kDa hGH, 6 X lo9 L/mol) was immobi- 
lized on microtiter plates. This antibody was previously identified to 
bind to an epitope distant from both receptor-binding sites of the hGH 
molecule. The antibody was loaded with rhGH by incubation of 0.25 
rig/well rhGH in assay buffer for 3 h at ambient temperature. After a 
wash step, 50 rig/well biotinylated rhGHBP in the absence or presence 
FIG. 1. Assay scheme of the hGH IFA. Immobilized mAb 7Bll binds 
hGH via its N-terminally located epitope overlapping with binding 
site 2. In a second incubation step, biotinylated rhGHBP, which is 
structurally identical to the hGH receptor ecto domain, binds to the 
complex, and the biotin moieties link to europium-labeled streptavi- 
din (STAV-Eu). 
of increasing concentrations of anti-hGH mAb 7811 binding to binding 
site 2 of the hGH molecule or of mAb 8Bll binding to binding site 1 of 
the molecule (K, for 22-kDa hGH, 7 X 10’ L/mol) was allowed to 
incubate overnight at 4 C. We hypothesized that two biotinylated mol- 
ecules of hGHBP could bind to each molecule of hGH. As binding of 
hGH receptors to the hGH molecule is of a sequential nature in which 
first binding site 1 of the hGH molecule has to be loaded to allow binding 
site 2-mediated association of a second receptor or binding protein 
molecule, mAb 7Bll should be able to prevent the association with the 
second rhGHBP molecule at sufficiently high concentrations of the mAb, 
retaining association of hGH biotinyl-rhGHBP on binding site 1 and 
thereby 50% of the maximally detectable signal. In contrast, mAb 8811 
prevented association at binding site 1 and, therefore, also abolished the 
sequential binding of hGHBP to binding site 2 of hGH; therefore, it 
should be able to displace the entire signal derived from the association 
of biotinyl rhGHBP with hGH. 
Results 
Epitope specificity of anti-hGH mAb 7Bll 
Cross-reactivity of mAb 7Bll to hGH-related molecules 
derived from comparison of 50% intercepts in competitive 
displacement experiments with increasing concentrations of 
the respective hGH variant or hGH fragment is shown in 
Table 1. The relative displacing potency of rhGH was set at 
100%. Of the hGH fragments tested, mAb 7B11 shows a high 
degree of cross-reaction with fragment l-134, representing 
roughly the first two thirds of the hGH sequence. A minor 
cross-reaction of 0.84% was detected with the fragment span- 
ning amino acid residues 15-125; the other tested hGH frag- 
ments were not recognized by this mAb. 
Twenty-two-kilodalton pituitary-derived hGH (AFP- 
4793B) showed 53.3% binding potency compared to recom- 
binant 22-kDa hGH. Twenty-kilodalton hGH (AFP-4286B) 
derived from pituitary extract exhibited 45.7% cross-reac- 
tion, corresponding to 86% displacing potency of pituitary- 
derived 22-kDa hGH. hPL, which shares 85% amino acid 
homology with hGH, has only 0.94% cross-reaction with 
mAb 7Bl1, indicating that the epitope recognized by this 
antibody has a high degree of heterology between hPL and 
22-kDa hGH. 
Neither N-terminally truncated variants lacking the first 7 
or 13 amino acid residues showed any cross-reaction with 
this mAb, indicating that its binding site overlapped or was 
near to the N-terminus of the hGH molecule. Finally, the 
hGH-CV variant showed 22.9% relative displacing potency, 
indicating that the epitope bound by mAb 7Bll might have 
one amino acid heterology compared to 22-kDa hGH. Figure 
2 shows a model of hGH in which the structural deviations 
from 22-kDa hGH of the des7 hGH molecule and the hGH-CV 
variant are indicated. The ellipse shows binding site 2, as 
TABLE 1. Cross-reaction of hGH-related molecules and hGH 
fragments with mAb 7Bll 
hGH variants hGH fragments 
rhGH (22 kDa) 100.00% aa 20 -40 <O.Ol% 
rhGH desr <O.Ol% aa 1-134 22.50% 
rhGH des’” <O.Ol% aa 15-125 0.84%’ 
rhGH CV 22.90% aa 95-134 <O.Ol% 
Pituitary hGH 53.30%’ aa 126-170 <O.Ol%’ 
Pituitary hGH (20 kDa) 45.70% aa 135-191 <0.01% 
hPL 0.94% aa 141-191 <O.Ol% 
Wild-type 22-kDa rhGH was used as reference and arbitrarily 
assigned 100% reactivity. aa, Amino acids. 
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epitope 
mAb 7B 
+ des7 hGH 
VE65V 0 hGH CV 
FIG. 2. Binding epitope of mAb 7Bll projected onto the x-ray crys- 
tallographically derived structure of the GH molecule adapted from 
the report of Abdel-Meguid et al. (24). The filledplus symbols indicate 
the amino acid residues missing in the des7 variant of rhGH; the full 
circles indicate the sites of mutation in the CV variant of rhGH. The 
mutations in the rhGH-CV molecule compared to 22-kDa pituitary 
hGH are described using the one-letter code for amino acids, stating 
first the code of the amino acid in the wild-type hGH, then the amino 
acid position, and last the amino acid introduced instead of the wild- 
type sequence in the hGH-CV variant. The ellipse depicts binding site 
2 ofthe hGH molecule’s interaction with its receptor (GH-R) according 
to the report if Cunningham et al. (13); the circle represents the 
epitope of mAb 7Bll. 
proposed by Cunningham et nl. (13); the circle shows the 
deduced binding epitope of mAb 7Bll. 
Functional relevance of mAb 7Bll binding to hGH 
Twenty-two-kilodalton hGH immobilized via mAb lOA 
binding an epitope distant from both receptor-binding sites 
of the hGH molecule was loaded with biotin-labeled rh- 
GHBP, and the displacing potencies of increasing concen- 
trations of mAb 7811 and mAb 8Bll were investigated as 
described above. mAb 8811 bound within binding site 1 of 
the hGH molecule. The experiment shows that mAb 7Bll 
maximally displaced 50% of the labeled binding protein mol- 
ecules, in keeping with blocking of binding site 2. In contrast, 
increasing concentrations of mAb 8Bll hindered the asso- 
ciation of hGH with rhGHBP on binding site 1 and, therefore, 
consecutively also on binding site 2 and displaced all labeled 
rhGHBP. Fifty percent displacement was achieved at 30 ng 
mAb 8811 /well. Results are shown in Fig. 3. 
Sensitivity and assay range 
Figure 4 shows two hGH IFA standard curves obtained by 
use of pituitary-derived hGH and rhGH (NIBSC 88/624); the 
mean +- 1 SD of three independent hGH-IFA standard curves 
ran in duplicate are displayed. The rhGH preparation was 
more potent than the pituitary-derived hGH. The lower de- 
tection limit (sensitivity), as defined by the mean ? 3 SD of 
a 20-fold zero standard determination, was 0.05 pg/L. The 
standard curve was linear in a double logarithmic plot of 
signal over hGH doses up to a concentration of at least 50 
l-%/L. 
50 -- 
40 -- 
o mAb7Bll 
30 *- 
20 
t 
A mAb6Bll 
a t 
1 IO 100 1000 10000 
mAb NW 
FIG. 3. Displacement of labeled hGHBP from immobilized hGH by 
increasing concentrations of anti-hGH mAbs. mAb 7Bl1, which is 
specific for binding site 2 of the hGH molecule, displaces maximally 
50% of labeled rhGHBP, whereas mAb 8Bl1, directed to binding site 
1 of the hGH molecule for the hGH receptor is capable of fully dis- 
placing the labeled hGH receptor ecto domain. 
counts 
1,ooo,wo 
rhGH standard 
NIBSC 88/624 
la/i 
rhGH signal 
ww mean * sd 
(n = 6) 
00 1,295 r 69 
01 1,897 f 91 
02 2,487 * 104 
05 4,188 + 243 
10 6,927 + 168 
20 12,192 + 430 
50 28,182 + 1,146 
100 50,943 + 2,576 
200 96,190 + 3,489 
500 215.185* 6.050 
1000 370,624*11.059 
0.1 
’ hGH (j@L) lo 
100 
FIG. 4. IFA standard curves for the reference preparation 88/624 of 
rhGH in sheep serum (circles) and pituitary-derived hGH (triangles). 
The error bars represent 1 SD of the signal obtained in three inde- 
pendent experiments, the signal obtained by use of rhGH (W624) is 
shown as the mean 2 SD for the calibrator concentrations used in the 
table on the right. 
Assay reproducibility 
Within-assay coefficients of variation were determined for 
three sera in an l&fold analysis. At concentrations of 0.43, 
5.3, and 19.2 pg/L, the within-assay coefficients of variation 
were 8.5%, 7.3%, and 6.1%, respectively. Between-assay re- 
producibility was analyzed by measurements of the same 
sera in eight independent assays. The respective between- 
assay coefficients of variation were 12.8%, 9.4%, and 7.9%. 
Znterference of endogenous hGHBP with the hGH IFA 
Fixed concentrations of hGH were preincubated with in- 
creasing concentrations of rhGHBP. One microgram per L 
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hGH, corresponding to a 45.5 pmol/L concentration, showed 
the highest susceptibility to interference from endogenous 
hGHBP. At 2000 pmol/L rhGHBP, the detected concentra- 
tion of hGH was 97%; at 5000 pmol/L rhGHBP, it was re- 
duced to 56%. Higher concentrations of hGH were less prone 
to interference. The results of this experiment are shown in 
Fig. 5. As the physiological concentration of hGHBP in serum 
samples is approximately 1000 pmol/L (range, 56-1187 
pmol/L) (27), no significant interference was expected from 
endogenous hGHBP concentrations in hGH results obtained 
by the IFA following this protocol. 
Linearity and recovery 
The linearity of the hGH IFA was evaluated by dilution of 
serum samples in sheep serum. The results obtained from the 
IFA were compared to the calculated results. The measured 
results were within a range of 89-104% of those expected, 
with a mean of 97.5%. The detailed linearity results are 
shown in Table 2. 
Recovery was evaluated by mixing equal volumes of dif- 
ferent sera with rhGH calibrators in sheep serum and as- 
saying these as unknowns. The measured results were within 
94.7% and 111.7% of those expected, with a mean 2 SD of 
100.5 2 7.1%. 
Specificity of the assay 
hPL and 20-kDa hGH, as well as hGH dimers were serially 
diluted in sheep serum and measured as unknowns in the 
hGH IFA. Cross-reaction of hPL in the hGH IFA was below 
0.001%; 10 mg/L hPL gave no detectable signal. Twenty- 
kilodalton rhGH showed a relative potency of 0.16% com- 
pared to 22-kDa hGH; the dose-response curve was linear in 
the detectable range between 200-1000 pg/L. Dimers had a 
relative potency of 111.6%. These specificity data indicate 
that hPL, which may circulate in extremely high levels dur- 
ing pregnancy, will not interfere in the assay. 
hGH measured 
In % of expected 
1 
loo- 
60- 
0 4vdL 
A14 pg,9R 
040 /IgiL 
hGH-BP (PM) 
FIG. 5. Interference of endogenous hGHBP with hGH measurements 
performed by the IFA. Increasing concentrations of rhGHBP were 
added to fixed concentrations of hGH and preincubated. Thereafter, 
the samples were analyzed in the IFA, and the results are displayed 
as the concentration measured as a percentage of that expected. Even 
at the lowest concentration of hGH tested (1 @g/L), the interference 
from hGHBP within physiological concentrations (52000 pmoLW was 
a negative bias of below 3%. 
TABLE 2. Linearity of two patient sera determined in the hGH 
IFA 
Serum samples Measured (fig/L) Expected C&L) % of expected 
Serum 1, direct 4.51 
1:2 2.35 2.25 104.2 
1:4 1.11 1.13 98.4 
1:s 0.50 0.56 88.7 
1:16 0.29 0.28 102.9 
Serum 2, direct 62.80 
1:2 31.60 31.40 100.6 
1:4 14.42 15.70 91.8 
1:s 7.45 7.85 94.9 
1:16 3.87 3.92 98.6 
Mean k SD 97.5 t 5.4 
Comparison of hGH IFA with polyclonal hGH RIA 
We decided to compare the hGH-IFA to the polyclonal 
competitive RIA because the latter method is the most widely 
applied technique for hGH measurement worldwide and is 
assumed to yield comparable results between different lab- 
oratories. When comparing the results from 128 serum sam- 
ples from different patients between the hGH IFA and the 
RIA, both using rhGH as the standard, the IFA yielded, on 
the average, 73.2% of the concentration determined by the 
RIA (Fig. 6A). This result indicates that serum samples, on 
the average, contain 27% of molecular forms of hGH that are 
recognized by RIA, but do not express both binding sites 1 
and 2 as measured in the IFA. When replacing the standard 
used in the RIA by pituitary-derived hGH, as most com- 
monly used throughout, and comparing the results to those 
from the IFA calibrated again by rhGH, the IFA detects, on 
the average, 30% of the RIA result (Fig. 6B). The major con- 
tribution to this heterology, as deduced from comparing Fig. 
6, A and B, is contributed by the heterology of standards; the 
remainder is determined by the existence of bioinactive hGH 
forms. The scatter of individual samples around the regres- 
sion line in the latter re 
9 
ression analysis is reflected by a 
correlation coefficient of r = 0.869, indicating that the degree 
of bioinactive hGH forms in circulation differs between in- 
dividuals. On an individual basis, the degree of immuno- 
functionally active hGH forms in serum samples, as calcu- 
lated by comparison of IFA and RIA results from assays both 
using rhGH as calibrators (Fig. 6A), varied between 52-93%. 
Comparison of hGH IFA with Nb2 cell bioassay 
Eighteen sera collected for GH determination in the Sec- 
tion of Pediatric Endocrinology at the Universitats-Kinder- 
klinik (Tubingen, Germany) were selected to cover a range 
between 1.0-25.8 pg/L by RIA. These sera were analyzed 
additionally in the Nb2 cell assay and by IFA. The correlation 
between RIA and Nb2 cell assay, both calibrated against 
pituitary-derived hGH IRP 80/505, was r2 = 0.84, with a 
regression line equation of ycNbZ) = 0.39 + 0.89x(,,,,. IFA 
results, derived from calibration with recombinant Interna- 
tional Reference Preparation 88/624, compared to RIA with 
r2 = 0.88 and a regression line of yeFA) = 0.04 + 0.54x0,,,. 
The agreement between Nb2 cell assay and the hGH IFA, as 
shown in Fig. 7, was higher than that of either of the methods 
compared to RIA, with r2 = 0.97, ycNb2) = -0.04 + 0.58x0,,,. 
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FIG. 6. Correlation of hGH measurements by RIA and IFA in 128 
sera selected from basal and stimulated sera of adult patients on the 
basis of their RIA result being within the detectable range of the RIA 
(~0.5 pg/L) and in the major clinical range ofinterest (520 pg/L). The 
latter criterion was chosen to avoid calculation of a biased regression 
line by single high sample points. In A, results are compared by use 
of rhGH (88/624) in both assays; in B, results from the IFA calibrated 
with rhGH are compared to those from a polyclonal hGH RIA using 
pituitary-derived calibrators. 
Clinical application of the hGH IFA 
The hGH levels determined in arginine infusion tests con- 
ducted for the investigation of suspected GH deficiency in 
adults are displayed in Fig. 8 for six patients who had pre- 
viously undergone pituitary surgery for nonfunctioning ad- 
enomas and who required replacement therapy with glu- 
cocorticoids, T,, and gonadal steroids. In the same figure, for 
comparison, the results of arginine-induced GH secretion in 
two healthy volunteers are displayed (the two upper lanes). 
hGH levels were also analyzed by IFA and RIA in acro- 
megalic patients before and in hourly intervals for 8 h after 
application of a single dose of 100 kg somatostatin (Oct- 
reotide, Sandoz, Basel, Switzerland). In patients with resid- 
ual activity of acromegaly after transsphenoidal surgery for 
a somatotropin-producing adenoma, both methods showed 
the expected decay in GH levels after the drug application to 
between 30-45% of baseline (data not shown). The ratio 
between the results measured in the RIA and those deter- 
mined by IFA did not change significantly during this phar- 
0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 
hGH @g/L) NbZ-cell assay 
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FIG. 7. Correlation of hGH measurements obtained by the Nb2 cell 
assay (26) and the hGH IFA. Eighteen sera were selected on the basis 
of hGH concentration, determined by RIA to cover a range between 
1.0-25.8 kg/L. 
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FIG. 8. hGH levels measured by IFA in arginine stimulation tests in 
six patients with hypopituitarism after transsphenoidal surgery for 
nonfunctioning pituitary adenoma (triangles) and in two healthy con- 
trols (circles). 
macokinetic study and was in keeping with the results of the 
regression analysis shown in Fig. 6. 
Discussion 
We described the development of an immunofunctional 
assay for the measurement of GH levels in human blood. In 
this sandwich-type assay, only those molecular forms of GH 
that possess both binding sites 1 and 2 for the GH receptor 
generate an assay signal. This is accomplished by immobi- 
lization of a monoclonal antibody binding to binding site 2 
of hGH and the use of labeled rhGHBP to bind binding site 
1 of the hGH molecule. The use of rhGHBP rather than a 
second monoclonal antibody to GH is essential for this pur- 
pose, because only the structural identity of hGHBP with the 
hGH receptor allows for the accurate monitoring of GH’s 
capability of binding to its receptor. As an epitope recognized 
by a monoclonal antibody spans over a maximum of 10 
amino acid residues (201, a monoclonal antibody could not 
representatively mimic the interaction of GH with its recep- 
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tor on binding site 1, which involves 31 amino acid side- 
chains (18). 
The immunofunctional hGH assay is suitable for clinical 
routine use, as characterized by its working range between 
0.1-100 pg hGH/L. We have shown that endogenous GHBP 
levels in physiological concentrations do not result in sig- 
nificant interference with the hGH results derived from the 
IFA method. By comparison of results from 128 sera mea- 
sured in both a competitive polyclonal RIA using the same 
rhGH reference preparation 88/624 and the IFA, it can be 
concluded that, on the average, 27% of molecular forms in 
circulation give rise to a signal in the RIA, but not in the IFA. 
From the design of the IFA, we conclude that these 27% of 
hGH forms in circulation do not possess both binding sites 
for the receptor and, therefore, would not be able to initiate 
a signal transduction process at target cells, which is known 
to require receptor dimerization. When comparing the re- 
sults obtained by use of the IFA and rhGH as the calibrator 
to those obtained from polyclonal RIA calibrated by use of 
pituitary hGH, the IFA results were, on the average, only 30% 
of those from the RIA. The major contribution to this dis- 
crepancy, however, is from the different potencies of the 
calibrators. Direct comparison of RIA results obtained by use 
of pituitary-derived VS. recombinant calibrator shows a de- 
cline in hGH levels to less than 50%. The remainder of the 
discrepancy between IFA and RIA results accounts for mo- 
lecular forms not recognized in the IFA, but giving a signal 
in the RIA. 
One possible limitation of the method is its relative overes- 
timation of hGH dimers. After binding to the immobilized mAb 
7811, some of the hGH dimer molecules appear to be capable 
of binding two labeled hGH receptor ecto domains (hGHBP). 
An interesting observation was that recombinant 20-kDa hGH 
showed a dose-response curve parallel to that of 22-kDa hGH, 
but with a potency of only 0.16% relative to that of 22-kDa hGH. 
The existing body of literature is controversial as to whether 
20-kDa hGH can activate the GH receptor. hPL, the concentra- 
tion of which in late pregnancy is known to exceed that of GH 
by a factor of 1000, shares 85% amino acid homology with hGH. 
At concentrations up to 10 mg/L, hPL does not result in a 
measurable signal in the hGH IFA. 
The use of biotin as a primary probe in the IFA described 
here allows for versatile end-point determination; the 
streptavidin-europium conjugate used by us can easily be 
replaced by a streptavidin-enzyme conjugate for calorimetric 
end-point determination or any other label attached to 
streptavidin for which a laboratory is equipped with the 
respective measurement device. This, in principle, allows for 
application of the IFA in any endocrine laboratory. 
Theoretically, bioassays, although more cumbersome in 
performance, could provide reliable estimates of biologically 
active GH levels in serum. The results of hGH determinations 
by bioassays, however, have to be interpreted with caution, 
bearing in mind that in these systems the interaction of hGH 
with receptors of other species, mostly rat GH receptors (28) 
or rat PRL receptors (29), is monitored. The employment of 
hGH receptors as expressed on IM9 cells in a competitive 
binding assay is limited by a lower detection limit of -2 
pg/L (30) due to the rather low affinity of the hGH receptor 
for its specific ligand, which is on the order of 1 nmol/L. 
Liver membrane RRAs lack specificity for hGH (31). The 
Nb2 cell assay (26), which employs rat lymphoma cells 
expressing a short form of the rat PRL receptor with a 
higher affinity for hGH than the hGH receptor with a K, 
of 1 x 10” L/mol appears to be the sole bioassay for hGH 
that can be performed with tolerable effort in large scale 
sample series and provides sufficient sensitivity to mea- 
sure GH levels in the relevant clinical range down to 0.1 
kg/L. In Fig. 7, we show very good agreement between the 
results of the Nb2 cell assay and the hGH IFA in 18 sera. 
Whether the agreement between the two methods is as 
high in all instances remains to be investigated by larger 
series of samples. Potential discrepant results from the 
Nb2 cell assay and the hGH IFA could be explained by the 
fact that the Nb2 cell assay studies the interaction of GH 
with a heterologous receptor and requires blocking of 
endogenous PRL by the addition of a neutralizing anti- 
body. Independently of these theoretical concerns, the per- 
formance and handling of the hGH IFA are substantially 
easier than those of the Nb2 cell assay because living cells 
are not used, even though an elegant modified version of 
the Nb2 cell assay has recently been described in this 
journal by Dattani et al. (32). 
The high degree of heterogeneity in results of hGH mea- 
surements performed by different immunoassays (1) poses a 
major problem in the standardization of cut-off levels for GH 
provocative testing. Until now, the highest degree of com- 
parability between results from different laboratories was 
achieved by application of polyclonal competitive immuno- 
assays. As a consequence of the variations in specificity of the 
antibodies employed, results differ even between these 
assays. 
As the diagnosis of GH deficiency results in GH replace- 
ment therapy, which implies the need for daily SC injections 
for the patient and substantial cost for the health care system, 
transparent and standardized diagnostic criteria have to be 
postulated for the establishment of this diagnosis. Determi- 
nation of GH levels in provocative tests presently is required 
for confirmation of the diagnosis and in many countries also 
for the reimbursement of therapy costs. We, therefore, con- 
sider crucial the standardization of the assay procedure and 
reference preparation used. 
For the purpose of harmonization of immunoassay mea- 
surements of hGH levels, a consensus has to be achieved with 
respect to the reference preparation of hGH used for cali- 
bration of these methods. Recombinant 22-kDa hGH has 
recently become available as an international reference prep- 
aration and represents a homogeneous, well defined hGH 
standard. For elimination of heterogeneity in assay results 
that are attributed to differences in epitope specificities, we 
propose the IFA method as a possible gold standard for hGH 
quantitation. 
We are currently using the IFA to establish empirical cut- 
off levels in hGH provocative testing by insulin tolerance test 
and arginine infusion. Additionally, we intend to address the 
question of changes in the ratio between immunoassayable 
and immunofunctionally active forms of hGH in different 
dynamic tests. 
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